News & Events about Immunogen Inc.
ImmunoGen (NASDAQ:IMGN Get Rating) had its price target hoisted by JPMorgan Chase & Co. from $8.00 to $9.00 in a research report sent to investors on Monday, Benzinga reports. The firm currently has a neutral rating on the biotechnology companys stock. Several other analysts have also commented on ...
ImmunoGen (NASDAQ:IMGN Get Rating) had its price target hoisted by JPMorgan Chase & Co. from $8.00 to $9.00 in a research report sent to investors on Monday, Benzinga reports. The firm currently has a neutral rating on the biotechnology companys stock. Several other analysts have also commented on ...
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (pivekimab) in combination...
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine (pivekimab) in...
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope PR Newswire PALM BEACH, Fla., Dec. 1, 2022 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The...